Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2020

Open Access 01-10-2020 | Enterostomy | Peritoneal Surface Malignancy

Systematic Review of Factors Affecting Quality of Life After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Authors: Maleen Leimkühler, MD, Judith E. K. R. Hentzen, MD, Patrick H. J. Hemmer, MD, Lukas B. Been, MD, PhD, Robert J. van Ginkel, MD, PhD, Schelto Kruijff, MD, PhD, Barbara L. van Leeuwen, MD, PhD, Geertruida H. de Bock, PhD

Published in: Annals of Surgical Oncology | Issue 10/2020

Login to get access

Abstract

Background

Previous studies have shown that, overall, quality of life (QoL) decreases within the first 3–6 months after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC), returning to baseline levels by 6–12 months. This systematic review aims to evaluate the factors affecting QoL after CRS + HIPEC within 12 months of surgery.

Methods

Electronic databases were investigated searching for articles reporting QoL with validated questionnaires up to September 2019. Risk of bias was assessed with the methodological index for non-randomized studies tool. The primary outcomes were short-term (< 6 months after surgery) and medium-term (6–12 months after surgery) determinants of QoL after CRS + HIPEC. Secondary outcomes were QoL and reported symptoms over time.

Results

We included 14 studies that used 12 different questionnaires. The reported data were collected prospectively or retrospectively for 1556 patients (dropout < 50% in four studies). Overall, studies showed diminished QoL within 3 months after surgery and a recovery to baseline or greater by 12 months. QoL was negatively influenced by higher age, female sex, prolonged operation time, extensive disease, residual disease, adjuvant chemotherapy, complications, stoma placement, and recurrent disease. QoL results were comparable between studies, with dropout rates above and below 50%.

Conclusions

QoL returns to baseline levels within 12 months after CRS + HIPEC provided the disease does not recur, and this recovery process is influenced by several factors.
Appendix
Available only for authorised users
Literature
1.
Al-Shammaa HA, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol. 2008;14(8):1159–1166.PubMedPubMedCentral
2.
Cao C, Yan TD, Black D, Morris DL. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2009;16(8):2152–2165.PubMed
3.
Deraco M, Baratti D, Kusamura S. Morbidity and quality of life following cytoreduction and HIPEC. Cancer Treat Res. 2007;134:403–418.PubMed
4.
Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–363.PubMed
5.
Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545–1550.PubMed
6.
Mahteme H, Hansson J, Berglund A, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: A preliminary study. Br J Cancer. 2004;90(2):403–407.PubMedPubMedCentral
7.
Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7(1):69–76.PubMed
8.
Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2(1):3-7800-2-3.
9.
Levine EA, Stewart 4th JH, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: Experience with 501 procedures. J Am Coll Surg. 2007;204(5):943–53; (discussion 953–5).PubMed
10.
Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245(1):104–109.PubMedPubMedCentral
11.
Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16(4 Suppl 6):83–97.PubMed
12.
Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric french study. J Clin Oncol. 2010;28(1):63–68.PubMed
13.
Esquivel J, Elias D, Baratti D, Kusamura S, Deraco M. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 2008;98(4):263–267.PubMed
14.
Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249(6):900–907.PubMed
15.
Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol. 2004;22(16):3284–3292.PubMed
16.
Gomez Portilla A, Barrios P, Rufian S, et al. Management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Eur J Surg Oncol. 2006;32(6):628–631.PubMed
17.
Robella M, Vaira M, Cinquegrana A, De Simone M. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Morbidity and postoperative outcomes. Minerva Chir. 2019;74(3):195–202.PubMed
18.
van Leeuwen BL, Graf W, Pahlman L, Mahteme H. Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol. 2008;15(3):745–753.PubMed
19.
Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–3743.PubMed
20.
Seretis C, Youssef H. Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: A systematic review. Eur J Surg Oncol. 2014;40(12):1605–1613.PubMed
21.
Shan LL, Saxena A, Shan BL, Morris DL. Quality of life after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy for peritoneal carcinomatosis: A systematic review and meta-analysis. Surg Oncol. 2014;23(4):199–210.PubMed
22.
Chia CS, Tan GHC, Lim C, Soo KC, Teo MCC. Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2905–2913.PubMed
23.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–1012.PubMed
24.
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.PubMed
25.
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–716.PubMed
26.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–174.PubMed
27.
Albertsmeier M, Hauer A, Niess H, Werner J, Graeb C, Angele MK. Quality of life in peritoneal carcinomatosis: a prospective study in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Dig Surg. 2014;31(4–5):334–340.PubMed
28.
Dodson RM, McQuellon RP, Mogal HD, et al. Quality-of-life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23:S772-S783.
29.
Hamilton TD, Taylor EL, Cannell AJ, McCart JA, Govindarajan A. Impact of major complications on patients’ quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2946–2952.PubMed
30.
Hill AR, McQuellon RP, Russell GB, Shen P, Stewart IV JH, Levine EA. Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. Ann Surg Oncol. 2011;18(13):3673–3679.PubMedPubMedCentral
31.
Hinkle NM, Botta V, Sharpe JP, Dickson P, Deneve J, Munene G. The impact of early recurrence on quality of life after cytoreduction with HIPEC. Am Surg. 2017;83(6):633–639.PubMed
32.
Kopanakis N, Argyriou E-, Vassiliadou D, et al. Quality of life after cytoreductive surgery and HIPEC: A single centre prospective study. J B U ON. 2018;23(2):488–493.
33.
Macrí A, Maugeri I, Trimarchi G, et al. Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitionaeal chemotherapy for peritioneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. In Vivo. 2009;23(1):147–150.PubMed
34.
McQuellon RP, Danhauer SC, Russell GB, et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2007;14(3):1105–1113.PubMed
35.
McQuellon R, Loggie B, Fleming R, Russell G, Lehman A, Rambo T. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001;27(1):65–73.PubMed
36.
Passot G, Bakrin N, Roux AS, et al. Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: A prospective study of 216 patients. Eur J Surg Oncol. 2014;40(5):529–535.PubMed
37.
Tsilimparis N, Bockelmann C, Raue W, et al. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Is it worth the risk? Ann Surg Oncol. 2013;20(1):226–232.PubMed
38.
Tuttle TM, Zhang Y, Greeno E, Knutsen A. Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2006;13(12):1627–1632.PubMed
39.
Bayat Z, Taylor EL, Bischof DA, McCart JA, Govindarajan A. Impairments in bowel function, social function and quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2020;27(1):124–131.PubMed
40.
Francescutti VA, Maciver AH, Stewart E, et al. Characterizing the patient experience of CS/HIPEC through in-depth interviews with patients: Identification of key concepts in the development of a patient-centered program. Ann Surg Oncol. 2019;26(4):1063–1070.PubMed
41.
Leo Swenne C, Cederholm K, Gustafsson M, Arakelian E. Postoperative health and patients’ experiences of efficiency and quality of care after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, two to six months after surgery. Eur J Oncol Nurs. 2015;19(2):191–197.PubMed
42.
Eriksson H, Haglund K, Leo Swenne C, Arakelian E. Patients’ experiences of postoperative health related to cytoreductive surgery and hyperthermic intraoperative chemotherapy. J Clin Nurs. 2014;23(1–2):201–210.PubMed
43.
Chia CS, Tan WJ, Wong JFS, et al. Quality of life in patients with peritoneal surface malignancies after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2014;40(8):909–916.PubMed
44.
Duzgun O, Sarici IS, Gokcay S. Short-term quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Istanb Med J. 2018;19(2):143–146.
45.
Tan WJ, Wong JFS, Chia CS, Tan GHC, Soo KC, Teo MCC. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An asian perspective. Ann Surg Oncol. 2013;20(13):4219–4223.PubMed
46.
Schmidt U, Dahlke M, Klempnauer J, Schlitt H, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. EJSO. 2005;31(1):53–58.PubMed
Metadata
Title
Systematic Review of Factors Affecting Quality of Life After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
Authors
Maleen Leimkühler, MD
Judith E. K. R. Hentzen, MD
Patrick H. J. Hemmer, MD
Lukas B. Been, MD, PhD
Robert J. van Ginkel, MD, PhD
Schelto Kruijff, MD, PhD
Barbara L. van Leeuwen, MD, PhD
Geertruida H. de Bock, PhD
Publication date
01-10-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 10/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08379-9

Other articles of this Issue 10/2020

Annals of Surgical Oncology 10/2020 Go to the issue

ASO Author Reflections

ASO Author Reflections: Lung Adenocarcinoma with Accidental Invisible Pleural Dissemination Lesions: Wait-and-See Strategy for Tumors with Indolent Biologic Characteristics

ASO Author Reflections

ASO Author Reflections: The Application of Transoral Robotic Thyroidectomy (TORT) for Papillary Thyroid Carcinoma

Breast Oncology

Evaluating Need for Additional Imaging and Biopsy After Oncoplastic Breast-Conserving Surgery

Health Services Research and Global Oncology

Warm and Welcoming: Is It What We Say or How We Say It?

Gynecologic Oncology

Should We Abandon Systematic Pelvic and Paraaortic Lymphadenectomy in Low-Grade Serous Ovarian Cancer?

Pancreatic Tumors

Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma